Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMPORTANT SHAREHOLDER DEADLINE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against The Spectranetics Corporation and Encourages Investors to Contact the Firm

Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado against The Spectranetics Corporation (“Spectranetics” or the “Company”) (NASDAQ: SPNC). Investors who purchased or otherwise acquired shares between February 19, 2015, and July 23, 2015, inclusive (the “Class Period”) are encouraged to contact the Firm immediately to discuss their legal options.

If you purchased shares of Spectranetics during the class period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Spectranetics manufactures and sells medical devices used in cardiovascular surgery. The complaint against Spectranetics alleges that: (1) increasing competition had adversely affected the Company; (2) that Spectranetics' sales force optimization efforts were not adequate and caused the Company to perform below expectations; and (3) that the Company lacked adequate internal controls. On July 23, 2015, Spectranetics reported results that fell below Wall Street’s expectations. The Company attributed the lowering of its guidance to competitive drug-coated balloon launches and ongoing sales team optimization. When this news was revealed to investors, shares fell by approximately 34%, to close at $24.83 per share.

If you purchased shares of Spectranetics during the Class Period you have until October 26, 2015 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com